Nurix Therapeutics (NASDAQ:NRIX) Receives New Coverage from Analysts at Jefferies Financial Group

by · The Cerbat Gem

Jefferies Financial Group initiated coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a report released on Friday, Marketbeat.com reports. The firm issued a buy rating and a $41.00 price target on the stock.

NRIX has been the topic of a number of other reports. HC Wainwright lifted their target price on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the stock a buy rating in a research note on Tuesday, June 18th. Oppenheimer upped their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the company an outperform rating in a report on Wednesday, September 4th. Needham & Company LLC cut their target price on Nurix Therapeutics from $31.00 to $29.00 and set a buy rating for the company in a research note on Friday, July 12th. JPMorgan Chase & Co. upped their price target on Nurix Therapeutics from $31.00 to $34.00 and gave the company an overweight rating in a research note on Monday, July 15th. Finally, Barclays raised their price objective on Nurix Therapeutics from $20.00 to $31.00 and gave the stock an overweight rating in a research report on Monday, July 15th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Nurix Therapeutics presently has a consensus rating of Moderate Buy and a consensus price target of $28.71.

View Our Latest Stock Analysis on Nurix Therapeutics

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock opened at $25.16 on Friday. Nurix Therapeutics has a 1-year low of $4.22 and a 1-year high of $26.31. The stock has a market cap of $1.24 billion, a P/E ratio of -8.62 and a beta of 2.22. The stock’s 50 day simple moving average is $23.36 and its 200-day simple moving average is $19.35.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last issued its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The company had revenue of $12.59 million during the quarter, compared to analysts’ expectations of $13.85 million. As a group, research analysts expect that Nurix Therapeutics will post -2.95 EPS for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 2,490 shares of the stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $51,468.30. Following the sale, the chief financial officer now directly owns 54,479 shares in the company, valued at approximately $1,126,080.93. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Gwenn Hansen sold 3,408 shares of the business’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $70,443.36. Following the completion of the transaction, the insider now directly owns 45,150 shares of the company’s stock, valued at approximately $933,250.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 2,490 shares of the company’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $51,468.30. Following the sale, the chief financial officer now owns 54,479 shares in the company, valued at $1,126,080.93. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 59,815 shares of company stock valued at $1,424,931 in the last 90 days. Company insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NRIX. Wellington Management Group LLP grew its stake in shares of Nurix Therapeutics by 41.6% during the fourth quarter. Wellington Management Group LLP now owns 205,324 shares of the company’s stock worth $2,119,000 after purchasing an additional 60,271 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Nurix Therapeutics by 67.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after acquiring an additional 3,793 shares during the last quarter. J.W. Cole Advisors Inc. purchased a new position in shares of Nurix Therapeutics in the 1st quarter valued at about $265,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Nurix Therapeutics by 27.3% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,904 shares of the company’s stock worth $454,000 after purchasing an additional 6,628 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Nurix Therapeutics by 75.6% during the first quarter. Russell Investments Group Ltd. now owns 53,542 shares of the company’s stock worth $787,000 after purchasing an additional 23,044 shares during the last quarter.

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Read More